logo
  • About Us
    • Company Overview
    • Vision / Mission / Values
    • Leadership
    • Clinical Advisory Board
    • Partnering
  • Our Approach
    • Technologies
    • Manufacturing
    • Publications
  • Pipeline
    • Pipeline
      • Autologous CAR-T
      • Allogeneic CAR-T
    • Expanded Access
  • Investors
    • Announcements
    • Corporate Governance
    • Corporate Deck & Presentations
      • Webcasts
      • Presentations
    • Financial Reports
    • Listing Documents
    • IR Contact
  • Newsroom
  • Careers
    • Join Us
  • Contact Us
EN 简
  • About Us
    • Company Overview
    • Vision / Mission / Values
    • Leadership
    • Clinical Advisory Board
    • Partnering
  • Our Approach
    • Technologies
    • Manufacturing
    • Publications
  • Pipeline
    • Pipeline
      • Autologous CAR-T
      • Allogeneic CAR-T
    • Expanded Access
  • Investors
    • Announcements
    • Corporate Governance
    • Corporate Deck & Presentations
      • Webcasts
      • Presentations
    • Financial Reports
    • Listing Documents
    • IR Contact
  • Newsroom
  • Careers
    • Join Us
  • Contact Us

Newsroom

  • Home -
  • Newsroom -
23
Sep 2019
CARsgen Announces Investigational CAR-T Therapy CT053 Granted PRIME Eligibility by the European Medicines Agency
Sep 23, 2019
31
Aug 2019
CARsgen Therapeutics Receives US FDA Orphan Drug Designation For Fully Human Anti-BCMA (B Cell Maturation Antigen) Autologous Chimeric Antigen Receptor (CAR) T Cells For The Treatment Of Multiple Myeloma
Aug 31, 2019
19
Jun 2019
CARsgen Therapeutics Receives IND Clearance for BCMA-CAR T cells from the U.S. FDA
Jun 19, 2019
01
Mar 2019
CARsgen Therapeutics Receives IND Clearance for BCMA-CAR T cells from the NMPA
Mar 01, 2019
29
Jan 2019
CARsgen Therapeutics Receives IND Clearance for GPC3-CAR T cells from the NMPA
Jan 29, 2019
04
Dec 2018
CARsgen Presents Preliminary Results of CAR-BCMA T Cell Therapy at ASH 2018
Dec 04, 2018
27
Aug 2018
CARsgen Appoints Dr. Hong MA as Senior Vice President of Clinical Development
Aug 27, 2018
02
Mar 2018
CARsgen Completed $60 Million Pre-C Financing Framework Agreements
Mar 02, 2018
10
Aug 2017
CARsgen Launches First-in-Class Anti-Claudin18.2 CAR-T Clinical Trial
Aug 10, 2017
30
Jun 2017
CARsgen Therapeutics Joins The Alliance for Regenerative Medicine
Jun 30, 2017
  • 1
  • ...
  • 8
  • 9
  • 10
Wechat
qr
Linkedin
  • About Us
    • Company Overview
    • Vision / Mission / Values
    • Leadership
    • Clinical Advisory Board
    • Partnering
  • Our Approach
    • Technologies
    • Manufacturing
    • Publications
  • Pipeline
    • Pipeline
    • Expanded Access
  • Investors
    • Announcements
    • Corporate Governance
    • Corporate Deck & Presentations
    • Financial Reports
    • Listing Documents
    • IR Contact
  • Newsroom
  • Careers
    • Join Us
  • Contact Us
Privacy Policy Terms of Use Developed by Euroland IR
Copyright ©2021-2025 CARsgen Therapeutics Holdings Limited